ANHL1522: A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative D

Protocol: 
AAAR3222
Phase: 
II

ANHL1522: A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative D

Are you Eligible? (Inclusion Criteria)

-Patients must be up to 29 years of age at the time of study entry.
-Patients must have a history of solid organ transplantation.
-Patients must not have received any prior radiation to any sites of measurable
disease.
-Patients must not have received any prior stem cell transplant.
-Patients must also meet all other eligibility criteria as outlined in the study
protocol.